Up to date knowledge from research like EV-302 and CheckMate 274 have been offered on the 2025 ASCO Genitourinary Cancers Symposium, reinforcing the...
Though carbon ion radiation led to a decline in urinary perform amongst sufferers with prostate most cancers, perform returned to regular after three...
Excessive pre-HIFU PSA ranges in intermediate-risk prostate most cancers have been linked to elevated recurrence and remedy failure, per ASCO 2025 analysis.Amongst sufferers...
The remedy mixture of Calquence (acalabrutinib) plus bendamustine and Rituxan (rituximab) was just lately granted full approval by the Meals and Drug Administration (FDA)...
